HER2 Breast Cancer

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.

Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.

Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

A discussion on the importance of prognostic tools for early stage breast cancer.

Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.

Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.

Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.

During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Ruta D. Rao, MD, discussed the case of 42-year-old woman with HER2-positive breast cancer.

William J. Gradishar, MD, discusses the current standard of care for patients with HER2-positive breast cancer, as well as some other promising therapies in this space.

The FDA granted a Fast Track designation to ARX788 as a single agent for the treatment of patients with advanced or metastatic HER2-positive breast cancer who received at least 1 prior anti-HER2 regimen in the metastatic setting.

The FDA granted approval to the Fc-engineered, monoclonal antibody margetuximab in combination with chemotherapy, as treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.

Patients with HER2-positive metastatic breast cancer and brain metastases treated with the combination of tucatinib, trastuzumab, and capecitabine had significantly lengthened the time to deterioration of health-related quality of life, according to the results of an analysis of the HER2CLIMB clinical trial presented during the 2020 San Antonio Breast Cancer Symposium.

William J. Gradishar, MD, discussed the effect tucatinib had on central nervous system metastases in patients with HER2-positive breast cancer.

To identify which patients with HER2-positive breast cancer are most likely to respond to fam-trastuzumab deruxtecan-nxki, investigators used a novel HER2 quantitative continuous score to provide a better objective and quantitative assessment of HER2 expression, data presented during the 2020 San Antonio Beast Cancer Symposium show.

Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.

Despite having similar disease characteristics and treatment patterns, elderly patients with HER2-positive advanced breast cancer aged ≥ 70 years experienced shorter chemotherapy durations than patients under the age of 70, as well as, poorer overall survival, and increased rates of adverse events in a real-world study.